chronic kidney disease steroid-induced diabetes mellitus
Conditions
Interventions
Alogliptin is administered to steroid-induced diabetes mellitus patients that are suffered from chronic kidney disease.
Sponsors
First Department of Medicine, Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) the patients that are not suffered from diabetes mellitus ( The patients have no thirsty, polyposia, polyuria, or body weight loss that is suspicious for diabetes mellitus. Fasting glucose level<126mg/dl, postplandial blood glucose level<200mg/dl, and HbA1c<6.1%) The patients have no diabetic retinopathy. 2) Diabetes mellitus is induced during steroid administration. At least, one of 3 components (fasting glucose level>126mg/dl, postplandial blood glucose level>200mg/dl, or HbA1c>6.1%) are detected during steroid administration.
Exclusion criteria
Exclusion criteria: 1) the patients that are suffered from diabetes mellitus The patients have thirsty, polyposia, polyuria or body weight loss that is suspicious for diabetes mellitus. Fasting glucose level>126mg/dl, postplandial blood glucose level>200mg/dl, and HbA1c>6.1% The patients have diabetic retinopathy. 2) the patients that are not suffered from severe alcholic liver damage 3) the patients that experience the administration of DPP-4 inhibitor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Fasting blood glucose level 2. Hemoglobin A1c 3. Postprandial blood glucose level in two hours after lunch | — |
Secondary
| Measure | Time frame |
|---|---|
| 4. HOMA-R (index of insulin resistance) 5. HOMA-beta (index of insulin secretion from pancreatic beta cell) 6. DPP-4 7. incretin (Glucagon-like peptide-1) 8. glucagon | — |
Countries
Japan
Contacts
Public ContactNaro Ohashi
Hamamatsu University School of Medicine First Department of Medicine
Outcome results
None listed